Despite demonstrating a higher rate of success compared with vehicle at all time points, EGP-437 for pain and inflammation in cataract surgery patients did not meet its co-primary endpoints in a phase 2b study.
Neither the proportion of patients with an anterior chamber cell count of zero at day 7 or the proportion of patients with a pain score of zero at day 1 showed statistical significance in the double-masked, randomized, vehicle-controlled trial of EGP-437 (iontophoretically delivered dexamethasone), according to a press release from EyeGate Pharmaceuticals.
“The efficacy results for
Uncategorized